Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials

Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Dhatri Karanam; Baruch D. Kuppermann; Francesco Bandello; Carl D. Regillo

doi:10.1038/s41433-021-01831-4

Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials

Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Dhatri Karanam, Baruch D. Kuppermann, Francesco Bandello, Carl D. Regillo

Research output: Contribution to journal › Editorial

5 Scopus citations

Original language	English
Pages (from-to)	679-680
Number of pages	2
Journal	Eye (Basingstoke)
Volume	36
Issue number	4
DOIs	https://doi.org/10.1038/s41433-021-01831-4
State	Published - Apr 2022
Externally published	Yes

Access to Document

10.1038/s41433-021-01831-4

Cite this

@article{141637e8e6ae49e8a8a27e2d350672af,

title = "Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials",

author = "Ashish Sharma and Nilesh Kumar and Nikulaa Parachuri and Dhatri Karanam and Kuppermann, {Baruch D.} and Francesco Bandello and Regillo, {Carl D.}",

note = "Funding Information: Dr. Kuppermann acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine.",

year = "2022",

month = apr,

doi = "10.1038/s41433-021-01831-4",

language = "English",

volume = "36",

pages = "679--680",

journal = "Eye (Basingstoke)",

issn = "0950-222X",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials

AU - Sharma, Ashish

AU - Kumar, Nilesh

AU - Parachuri, Nikulaa

AU - Karanam, Dhatri

AU - Kuppermann, Baruch D.

AU - Bandello, Francesco

AU - Regillo, Carl D.

N1 - Funding Information: Dr. Kuppermann acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85118380268&partnerID=8YFLogxK

U2 - 10.1038/s41433-021-01831-4

DO - 10.1038/s41433-021-01831-4

M3 - Editorial

C2 - 34718339

AN - SCOPUS:85118380268

SN - 0950-222X

VL - 36

SP - 679

EP - 680

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

IS - 4

ER -